PDCD1 and non-small cell lung carcinoma: Nivolumab, an immune checkpoint inhibitor (ICI) directed against the programmed cell death-1 (PD-1) protein, is currently available as a further line of treatment for NSCLC patients with either squamous or non-squamous histology [1, 3].